Vaccitech (VACC) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VACC shares.
View VACC analyst ratings or view top-rated stocks.

2 brokers have issued 1-year price objectives for Vaccitech's shares. Their VACC share price forecasts range from $7.00 to $16.00. On average, they anticipate the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 412.8% from the stock's current price.
View analysts price targets for VACC or view top-rated stocks among Wall Street analysts.

Vaccitech's stock was trading at $2.35 at the beginning of 2023. Since then, VACC stock has increased by 5.1% and is now trading at $2.47.
View the best growth stocks for 2023 here.

Vaccitech saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 20,400 shares, an increase of 43.7% from the April 30th total of 14,200 shares. Based on an average daily trading volume, of 52,800 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the company's stock are short sold.
View Vaccitech's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our VACC earnings forecast.

Vaccitech plc (NASDAQ:VACC) posted its quarterly earnings results on Friday, March, 24th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.12. The business had revenue of $6.46 million for the quarter, compared to analysts' expectations of $3.07 million. Vaccitech had a negative trailing twelve-month return on equity of 6.33% and a negative net margin of 51.19%.

(VACC) raised $110 million in an IPO on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

Vaccitech trades on the NASDAQ under the ticker symbol "VACC."

Vaccitech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Liontrust Investment Partners LLP (1.19%), Ipswich Investment Management Co. Inc. (0.07%) and Renaissance Technologies LLC (0.03%). Insiders that own company stock include Christopher Ellis, Graham Griffiths, Joseph Scheeren, Karen A Dawes, M&G Investment Management Ltd, Robin Wright, Sciences Innovation Plc Oxford and William Enright.
View institutional ownership trends.

Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VACC stock can currently be purchased for approximately $2.47.

Vaccitech (NASDAQ:VACC) has a market capitalization of $94.72 million and generates $44.70 million in revenue each year. The company earns $5.34 million in net income (profit) each year or ($0.40) on an earnings per share basis.

Vaccitech's mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The official website for the company is www.vaccitech.co.uk. The company can be reached via phone at 44-18-6581-8808 or via email at ir@vaccitech.co.uk..